Search clinical trials for: fruquintinib sintilimab

Total 518 results

Wuhan Union Hospital, China

Not yet recruiting

Fruquintinib Combined With Sintilimab as Second-line Therapy for Gastric or Gastro-esophageal Junction Adenocarcinoma

Stomach Neoplasms

China
RenJi Hospital

Active, not recruiting

Efficacy and Safety of Fruquintinib With Sintilimab as First-line Therapy in Gastric Cancer

Stomach Neoplasms

China
Chinese PLA General Hospital

Unknown

Phase II Study to Evaluate the Efficacy and Safety of Fruquintinib Plus Sintilimab as Third-line Therapy for Colorectal Cancer

Metastasis Colorectal Cancer

China
Hutchmed

Recruiting

: A Phase Ib/II Study To Evaluate Fruquintinib Monotherapy Or Plus Sintilimab In Advanced Solid Tumors

Advanced Solid Tumor

China
AIPING ZHOU

Unknown

Phase II Trial of Fruquintinib With Sintilimab in Treating Selected Refractory Metastatic Colorectal Cancer Patients

Colorectal Cancer

China
Henan Cancer Hospital

Recruiting

Fruquintinib in Combination With Sintilimab and CAPEOX as First-line Treatment for G/GEJ Cancer

Metastatic Gastroesophageal Junction Adenocarcinoma

China
Henan Cancer Hospital

Recruiting

Conversion Therapy of Fruquintinib in Combination With Sintilimab and SOX in Unresectable Gastric Cancer

Gastric Cancer

China
The First Affiliated Hospital of Xiamen University

Recruiting

Radiotherapy in Combination With Sintilimab，GM-CSF and Fruquintinib in Patients With MSS mCRC

Colorectal Neoplasms

China
Zhejiang Cancer Hospital

Recruiting

Phase II Study of Fruquintinib Combined With Sintilimab and TACE for Inoperable Primary Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Wuhan Union Hospital, China
Huazhong University of Science and Technology

Recruiting

Oral Inulin in Combination With Fruquintinib Plus Sintilimab as Third- or Further-line Treatment in Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

China
Xiaofeng Chen

Recruiting

XELOX Combined With Fruquintinib and Sintilimab Regimen Conversion Therapy for Gastric Cancer/Gastroesophageal Junction Adenocarcinoma Only With Liver and/or Retroperitoneal Lymph Node Metastasis, a Prospective Single-arm, Multicenter Study

Gastric Cancer/Gastroesophageal Junction Adenocarcinoma

China
Cancer Institute and Hospital, Chinese Academy...

Recruiting

FMT Combined With Immune Checkpoint Inhibitor and TKI in the Treatment of CRC Patients With Advanced Stage

Colorectal Neoplasms Malignant

China
Second Affiliated Hospital of Nanchang University

Not yet recruiting

Clinical Study of Fruquintinib Combined With Sintilimab and XELOX Regimen in the Treatment of Advanced Cancer

Gastric Cancer
Zhejiang Cancer Hospital

Not yet recruiting

Clinical Study of Short-course Radiotherapy Followed by Fruquintinib Plus Sintilimab vs Bevacizumab Plus Capecitabine as First Line Treatment in Advanced mCRC

Metastatic Colorectal Cancer | Metastatic Colorectal Adenocarcinoma | CRC

China
Hutchison Medipharma Limited

Withdrawn

Study of Fruquintinib (HMPL-013) in High Risk Patients With Advanced NSCLC

Lung Cancer

China
Zhen-Yu Ding

Completed

A Phase II Study on Dose Optimization of Fruquintinib in Elderly mCRC Patients Refractory to Standard Treatment（DOFEMCRC） (DOFEMCRC)

Colorectal Cancer

China
Hutchison Medipharma Limited

Recruiting

Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2)

Advanced Renal Cell Carcinoma

China
Hutchison Medipharma Limited

Completed

Fruquintinib Food Effect and Proton Pump Inhibitor Study

Food-drug Interaction | Drug Interaction

United States
Fudan University

Recruiting

Fruquintinib in the Treatment of Soft Tissue Sarcoma

Soft Tissue Sarcoma

China
Shanghai Zhongshan Hospital

Recruiting

Fruquintinib as a Maintenance Therapy Following First-line Treatment for Metastatic Colorectal Cancer

Colo-rectal Cancer

China
Peking University

Unknown

Real World Study of Regorafenib Versus Fruquintinib in Colorectal Cancer

Colorectal Cancer

China
Tianjin Medical University Cancer Institute and...

Recruiting

Fruquintinib Combined With TAS102 for Advanced Gastric Cancer

Gastric Cancer

China
Sichuan University

Unknown

Fruquintinib as Second-line Treatment for Advanced/Metastatic Biliary Tract Adenocarcinoma (FSTAMBTA)

Biliary Tract Adenocarcinoma

China
The First Affiliated Hospital of Zhengzhou University

Not yet recruiting

A Phase II Clinical Study of Fruquintinib Combined With RC48 in the Treatment of Previously Treated HER2-positive Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (G/GEJ) Cancer

Gastric Cancer

China
Beijing Tiantan Hospital

Recruiting

Exploratory Study of PD-1 Neoadjuvant Treatment of Recurrent Meningioma

Meningioma, Malignant

China
Fudan University

Recruiting

Fruquintinib With mFOLFOX6/FOLFIRI as First-Line Therapy for Conversion Surgery in mCRC

Colorectal Cancer

China
Hutchmed

Completed

Fruquintinib Renal Impairment Study

Renal Impairment

United States
Hutchmed

Completed

Fruquintinib Hepatic Impairment Study

Hepatic Impairment

United States
Hutchmed

Completed

A Phase IV Study of Elunate® (Fruquintinib) in Chinese Patients

Patient Safety

China
Hutchison Medipharma Limited
Fudan University

Completed

Phase I Study of Fruquintinib(HMPL-013) in Patients With Advanced Solid Tumors

Tumor

China
RemeGen Co., Ltd.

Recruiting

A Study of RC88 Combined With Sintilimab for Advanced Solid Tumours

Advanced Solid Tumours

China
The First Affiliated Hospital with Nanjing Medical...

Recruiting

Fruquintinib Combined With Sintilimab and Chemotherapy in the Treatment of Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

China
Huazhong University of Science and Technology

Recruiting

Cadonilimab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With MSS CRC

Colorectal Cancer

China
Hutchison Medipharma Limited
Sun Yat-sen University; Fudan University

Completed

A Phase Ib Study of Fruquintinib in 3rd Line mCRC

Colorectal Cancer

China
Hutchison Medipharma Limited

Completed

Food Effect Study of Single Dose of Fruquintinib (HMPL-013) in Healthy Subjects

Food Effect of Fruquintinib in Health Subjects

China
Hutchison Medipharma Limited

Completed

A Mass Balance Study to Investigate the Absorption, Metabolism, and Excretion Of [14C] Fruquintinib

Healthy

China
The First Affiliated Hospital with Nanjing Medical...

Recruiting

Fruquitinib Combined With Camrelizumab in Non MSI-H/dMMR Refractory Colorectal Cancer

Colorectal Neoplasm

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A PK Similarity Study of Two Sintilimab Products Produced by Different Processes in Advanced or Metastatic NSCLC Patients

Advanced or Metastatic NSCLC

China
Fudan University

Recruiting

A Study of PD-1 Inhibitors Combined With Fruquintinib and Chemotherapy in First-line Treatment of HER2-negative Advanced G/GEJ Cancer (G/GEJ cancer)

Gastric Cancer/Adenocarcinoma of Esophagogastric Junction

China
Fujian Cancer Hospital

Not yet recruiting

PARP Inhibitor CVL218 in Combination Therapy for Patients With Advanced Solid Tumors

Advanced Solid Tumor
Sun Yat-sen University

Recruiting

Fruquintinib Combined With TAS-102 in the Treatment of Patients With Advanced Metastatic CRC

Metastatic Colorectal Cancer

China
Takeda

Available

Expanded Access to TAK-113 for Adults With Metastatic Colorectal Cancer (mCRC)

Colorectal Cancer
Peking University People's Hospital

Completed

Fruquintinib-based Treatment for Refractory Bone and Soft Tissue Sarcomas After Several Lines of TKIs' Resistance

Soft Tissue Sarcoma | Bone Sarcoma | Refractory Tumor

China
Huazhong University of Science and Technology

Active, not recruiting

Tislelizumab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With Advanced CRC

Patients With Advanced Metastatic Colorectal Cancer

China
Fudan University

Recruiting

Fruquintinib Combined With TAS-102 in Refractory Metastatic Colorectal Cancer

Metastatic Colorectal Cancer | Colorectal Cancer | Refractory Colorectal Carcinoma

China
Innovent Biologics (Suzhou) Co. Ltd.
Innovent Biologics (USA), Inc.

Withdrawn

A Platform Study of Novel Immunotherapy Products in Participants With Previously Treated Unresectable or Metastatic Cutaneous Melanoma

Metastatic Cutaneous Melanoma | Unresectable Cutaneous Melanoma

United States, Germany, France, Australia, Spain, Switzerland, United Kingdom
Genor Biopharma Co., Ltd.
Hutchison Medipharma Limited

Recruiting

Safety and Efficacy of Genolimzumab (GB226) in Combination With Fruquintinib

Metastatic Non-small Cell Lung Cancer

China
Sun Yat-sen University

Recruiting

Efficacy of Modified Fruquintinib in Colorectal Cancer Liver Metastases: A Phase II Study

Colorectal Cancer Metastatic

China
RenJi Hospital
Shanghai Zhongshan Hospital

Not yet recruiting

Fruquintinib and Serplulimab Combination Therapy for First-line Treatment of Non-clear Cell Renal Cell Carcinoma: A Prospective Multicenter Study

First-line Treatment of Non-clear Renal Cell Carcinoma
Sun Yat-sen University
Hutchmed; BeiGene

Not yet recruiting

Tislelizumab Combined With Fruquintinib for Metastatic pMMR/MSS Colorectal Cancer

Metastatic Colorectal Cancer | mCRC

China

3

Subscribe